Table 2.
Effect of LSD family on drug resistance
| Enzyme | Cancer type | Drug | Effect or mechanism | Reference |
|---|---|---|---|---|
| LSD1 | breast cancer | adriamycin | increase the ability of mammary gland formation and cancer stem cell potential | 259 |
| hepatocellular carcinoma | sorafenib | improve the stability of p65 protein, and activate NF-κB consequently; inhibit the expression of spirgle1 and APC to maintain the viability of Lgr5+ cells | 262,265 | |
| gastric cancer | oxaliplatin | increase the expression of CD44, SOX2 and OCT4, and promote chemoresistance | 264 | |
| thyroid cancer | doxorubicin | increase cancer stemness by activating Wnt/β-catenin signaling pathway | 266 | |
| NSCLC | gefitinib | bind with FTH1P3 and TIMP3 promoter region to strengthen cell resistance to gefitinib | 269 | |
| hepatocellular carcinoma | oxaliplatin | activate the LINC01134-SP1-p62 axis | 271 | |
| LSD2 | breast cancer | DAC (a DNMT inhibitor) | knocking down LSD2 can inhibit cell clonogenic ability, induce cell apoptosis and block cells in S phase | 278 |
| ovarian cancer | cisplatin | inhibition of LSD2 decrease the level of DNA damage repair gene DCLRE1B | 280 |